CEL-SCI Corp Reports Director/Officer Changes

Ticker: CVM · Form: 8-K · Filed: Apr 23, 2024 · CIK: 725363

Sentiment: neutral

Topics: leadership-change, board-of-directors, officer-appointment

TL;DR

CEL-SCI board shakeup, new officers appointed.

AI Summary

CEL-SCI Corporation filed an 8-K on April 23, 2024, reporting changes effective April 19, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future company direction and performance.

Key Players & Entities

FAQ

What specific changes were made regarding directors or officers?

The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.

When were these changes effective?

The earliest event reported was effective April 19, 2024.

What is the primary business of CEL-SCI Corporation?

CEL-SCI Corporation is in the Biological Products sector, specifically Biological Products (No Diagnostic Substances).

Where are CEL-SCI Corporation's principal executive offices located?

The principal executive offices are located at 8229 Boone Boulevard, Suite 802, Vienna, Virginia 22182.

What is the filing date of this 8-K report?

The report was filed on April 23, 2024.

Filing Stats: 803 words · 3 min read · ~3 pages · Grade level 13.9 · Accepted 2024-04-23 17:00:57

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CEL-SCI CORPORATION Date: April 23, 2024 By: /s/ Patricia Prichep Patricia B. Prichep Senior Vice President of Operations 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing